Babon Jenny Aurielle B, DeNicola Megan E, Blodgett David M, Crèvecoeur Inne, Buttrick Thomas S, Maehr René, Bottino Rita, Naji Ali, Kaddis John, Elyaman Wassim, James Eddie A, Haliyur Rachana, Brissova Marcela, Overbergh Lut, Mathieu Chantal, Delong Thomas, Haskins Kathryn, Pugliese Alberto, Campbell-Thompson Martha, Mathews Clayton, Atkinson Mark A, Powers Alvin C, Harlan David M, Kent Sally C
Department of Medicine, Division of Diabetes, Diabetes Center of Excellence, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Laboratory for Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium.
Nat Med. 2016 Dec;22(12):1482-1487. doi: 10.1038/nm.4203. Epub 2016 Oct 31.
A major therapeutic goal for type 1 diabetes (T1D) is to induce autoantigen-specific tolerance of T cells. This could suppress autoimmunity in those at risk for the development of T1D, as well as in those with established disease who receive islet replacement or regeneration therapy. Because functional studies of human autoreactive T cell responses have been limited largely to peripheral blood-derived T cells, it is unclear how representative the peripheral T cell repertoire is of T cells infiltrating the islets. Our knowledge of the insulitic T cell repertoire is derived from histological and immunohistochemical analyses of insulitis, the identification of autoreactive CD8 T cells in situ, in islets of human leukocyte antigen (HLA)-A2 donors and isolation and identification of DQ8 and DQ2-DQ8 heterodimer-restricted, proinsulin-reactive CD4 T cells grown from islets of a single donor with T1D. Here we present an analysis of 50 of a total of 236 CD4 and CD8 T cell lines grown from individual handpicked islets or clones directly sorted from handpicked, dispersed islets from nine donors with T1D. Seventeen of these T cell lines and clones reacted to a broad range of studied native islet antigens and to post-translationally modified peptides. These studies demonstrate the existence of a variety of islet-infiltrating, islet-autoantigen reactive T cells in individuals with T1D, and these data have implications for the design of successful immunotherapies.
1型糖尿病(T1D)的一个主要治疗目标是诱导T细胞产生自身抗原特异性耐受性。这可以抑制有T1D发病风险的人群以及接受胰岛替代或再生治疗的已患病人群的自身免疫反应。由于对人类自身反应性T细胞应答的功能研究在很大程度上仅限于外周血来源的T细胞,尚不清楚外周T细胞库对浸润胰岛的T细胞的代表性如何。我们对胰岛炎T细胞库的了解来自于对胰岛炎的组织学和免疫组织化学分析、在人类白细胞抗原(HLA)-A2供体的胰岛中原位鉴定自身反应性CD8 T细胞,以及从一名患有T1D的单一供体的胰岛中分离并鉴定DQ8和DQ2-DQ8异二聚体限制性、胰岛素原反应性CD4 T细胞。在此,我们对从9名患有T1D的供体中挑选的单个胰岛或从挑选出的分散胰岛中直接分选的克隆所培养的236个CD4和CD8 T细胞系中的50个进行了分析。其中17个T细胞系和克隆对多种研究的天然胰岛抗原以及翻译后修饰的肽有反应。这些研究证明了T1D患者中存在多种浸润胰岛、对胰岛自身抗原有反应的T细胞,这些数据对成功免疫疗法的设计具有启示意义。